Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) has been granted a patent for its lead therapeutic candidate MB-204 by the Japanese Patent Office (JPO) covering composition of matter and methods of use claims.
MB-204 is a novel fluorinated analogue of istradefylline, an approved adenosine A2A receptor antagonist used in the treatment of Parkinson’s disease, and has demonstrated robust preclinical efficacy in models of depression and multiple models of autism.
In a statement, Rod Matheson, CEO of Marvel, commented, “This represents the second major jurisdiction to grant a composition-of-matter patent for our lead molecule MB-204. Securing patent protection in Japan significantly strengthens our global intellectual property portfolio and further enhances the long-term value of MB-204 as we advance toward clinical development.”
